170 related articles for article (PubMed ID: 19729501)
21. Long-term persistence of gene expression from adeno-associated virus serotype 5 in the mouse airways.
Sumner-Jones SG; Davies LA; Varathalingam A; Gill DR; Hyde SC
Gene Ther; 2006 Dec; 13(24):1703-13. PubMed ID: 16855618
[TBL] [Abstract][Full Text] [Related]
22. Retinal degeneration is slowed in transgenic rats by AAV-mediated delivery of FGF-2.
Lau D; McGee LH; Zhou S; Rendahl KG; Manning WC; Escobedo JA; Flannery JG
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3622-33. PubMed ID: 11006261
[TBL] [Abstract][Full Text] [Related]
23. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.
Huttner NA; Girod A; Perabo L; Edbauer D; Kleinschmidt JA; Büning H; Hallek M
Gene Ther; 2003 Dec; 10(26):2139-47. PubMed ID: 14625569
[TBL] [Abstract][Full Text] [Related]
24. Receptor targeting of adeno-associated virus vectors.
Büning H; Ried MU; Perabo L; Gerner FM; Huttner NA; Enssle J; Hallek M
Gene Ther; 2003 Jul; 10(14):1142-51. PubMed ID: 12833123
[TBL] [Abstract][Full Text] [Related]
25. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap.
Conway JE; Rhys CM; Zolotukhin I; Zolotukhin S; Muzyczka N; Hayward GS; Byrne BJ
Gene Ther; 1999 Jun; 6(6):986-93. PubMed ID: 10455400
[TBL] [Abstract][Full Text] [Related]
26. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.
Skaricic D; Traube C; De B; Joh J; Boyer J; Crystal RG; Worgall S
Virology; 2008 Aug; 378(1):79-85. PubMed ID: 18556039
[TBL] [Abstract][Full Text] [Related]
27. Assessment of a passive immunity mouse model to quantitatively analyze the impact of neutralizing antibodies on adeno-associated virus-mediated gene transfer.
Sun L; Tu L; Gao G; Sun X; Duan J; Lu Y
J Immunol Methods; 2013 Jan; 387(1-2):114-20. PubMed ID: 23063691
[TBL] [Abstract][Full Text] [Related]
28. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization.
Mori K; Gehlbach P; Yamamoto S; Duh E; Zack DJ; Li Q; Berns KI; Raisler BJ; Hauswirth WW; Campochiaro PA
Invest Ophthalmol Vis Sci; 2002 Jun; 43(6):1994-2000. PubMed ID: 12037010
[TBL] [Abstract][Full Text] [Related]
29. Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency.
Hacker UT; Wingenfeld L; Kofler DM; Schuhmann NK; Lutz S; Herold T; King SB; Gerner FM; Perabo L; Rabinowitz J; McCarty DM; Samulski RJ; Hallek M; Büning H
J Gene Med; 2005 Nov; 7(11):1429-38. PubMed ID: 15945124
[TBL] [Abstract][Full Text] [Related]
30. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes.
Maersch S; Huber A; Büning H; Hallek M; Perabo L
Virology; 2010 Feb; 397(1):167-75. PubMed ID: 19926109
[TBL] [Abstract][Full Text] [Related]
31. Transient expression of genes delivered to newborn rat liver using recombinant adeno-associated virus 2/8 vectors.
Flageul M; Aubert D; Pichard V; Nguyen TH; Nowrouzi A; Schmidt M; Ferry N
J Gene Med; 2009 Aug; 11(8):689-96. PubMed ID: 19455564
[TBL] [Abstract][Full Text] [Related]
32. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.
Moskalenko M; Chen L; van Roey M; Donahue BA; Snyder RO; McArthur JG; Patel SD
J Virol; 2000 Feb; 74(4):1761-6. PubMed ID: 10644347
[TBL] [Abstract][Full Text] [Related]
33. Immune response against gene therapy vectors: influence of synovial fluid on adeno-associated virus mediated gene transfer to chondrocytes.
Cottard V; Valvason C; Falgarone G; Lutomski D; Boissier MC; Bessis N
J Clin Immunol; 2004 Mar; 24(2):162-9. PubMed ID: 15024183
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
[TBL] [Abstract][Full Text] [Related]
35. Neutralizing Antibodies Against Adeno-Associated Virus (AAV): Measurement and Influence on Retinal Gene Delivery.
Desrosiers M; Dalkara D
Methods Mol Biol; 2018; 1715():225-238. PubMed ID: 29188517
[TBL] [Abstract][Full Text] [Related]
36. Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera.
Shin SK; Ha SK; Lee KW; Yoo TH; Yun SR; Yoon SH; Kim SJ; Lee SK; Heo TH
J Pharm Biomed Anal; 2010 Jun; 52(2):289-93. PubMed ID: 20133098
[TBL] [Abstract][Full Text] [Related]
37. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors.
Veron P; Leborgne C; Monteilhet V; Boutin S; Martin S; Moullier P; Masurier C
J Immunol; 2012 Jun; 188(12):6418-24. PubMed ID: 22593612
[TBL] [Abstract][Full Text] [Related]
38. The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector.
Liu Q; Huang W; Zhao C; Zhang L; Meng S; Gao D; Wang Y
J Med Virol; 2013 Sep; 85(9):1550-6. PubMed ID: 23852678
[TBL] [Abstract][Full Text] [Related]
39. Development of a Chemiluminescent ELISA Method for the Detection of Total Anti-Adeno Associated Virus Serotype 9 (AAV9) Antibodies.
Kavita U; Dai Y; Salvador L; Miller W; Adam LP; Levesque PC; Zhang YJ; Ji QC; Pillutla RC
Hum Gene Ther Methods; 2018 Dec; 29(6):237-250. PubMed ID: 30351228
[TBL] [Abstract][Full Text] [Related]
40. Effect of adeno-associated virus-specific immunoglobulin G in human amniotic fluid on gene transfer.
Boyle MP; Enke RA; Mogayzel PJ; Guggino WB; Martin DB; Agarwal S; Zeitlin PL
Hum Gene Ther; 2003 Mar; 14(4):365-73. PubMed ID: 12659677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
